IBRX
ImmunityBioCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Q1 preliminary revenue growth, expanding ANKTIVA geographic reach, and a fully enrolled QUILT-2.005 study support a real commercial-plus-regulatory path if the upcoming 10-Q validates the preliminary figures and 2026 regulatory milestones stay on track [#8-K-2026-04-09].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -7.1.
What can break
Formal Q1 2026 results could disappoint versus the April 9 preliminary figures.
Momentum
88
Value
41
Sentiment
42
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.50 · Bull $11.00 · Bear $4.50
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $13.00
Why
Momentum88 · Δ7d -7.1
Value41 · Δ7d +0.1
Sentiment42 · Δ7d +0.8
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
88
26% active weight
Current posture
7d trendSoftening
Δ7d
-7.1
Δ21d
+19.4
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
42
34% active weight
Current posture
7d trendFlat
Δ7d
+0.8
Δ21d
+10.7
Why this grade
Composite grade C. Momentum 88.4 / Value 41.1 / Sentiment 41.8
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$8.45B
Beta
-0.02
Shares Out
1.05B
P/E (TTM) · Derived
-21.1
P/S (TTM)
24.82
P/FCF (TTM) · Derived
-25.89
Rev YoY
+167.6%
EPS YoY
+305.4%
Gross Margin
+87.9%
Op Margin
-315.8%
Net Debt
$601.85M
Current Ratio
6.67
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology